Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint…

Overview of attention for article published in Journal for Immunotherapy of Cancer, June 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

So far, Altmetric has seen 1 Wikipedia article.

Galunisertib (LY2157299) is a small molecular experimental cancer drug in development by Eli Lilly.

This page shows the most recent Wikipedia articles that mention this research output.

Click here to find out how to access more activity.